Synonyms: hRS7-SN-38-ADC | IMMU-132 | sacituzumab govitecan-hziy | Trodelvy®
sacituzumab govitecan is an approved drug (FDA (2020), EMA (2021))
Compound class:
Antibody
Comment: IMMU-132 is an antibody-drug conjugate (ADC) with SN-38 (the active metabolite of the topoisomerase inhibitor irinotecan) covalently linked to an anti-TROP-2 monoclonal antibody (see patent US8574575 [1]) [2-3,5]. TROP-2 is a transmembrane glycoprotein, cell surface antigen which has oncogenic activity in cancers of epithelial origin [6], but expression is restricted in normal tissue. Directing SN-38 to cancer cells via TROP-2 binding is predicted to limit toxicity towards healthy tissue/cells.
|
Classification | |
Compound class | Antibody |
Approved drug? | Yes (FDA (2020), EMA (2021)) |
International Nonproprietary Names | |
INN number | INN |
10097 | sacituzumab govitecan |
Synonyms |
hRS7-SN-38-ADC | IMMU-132 | sacituzumab govitecan-hziy | Trodelvy® |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 559 |
Other databases | |
GtoPdb PubChem SID | 249565933 |
Search PubMed clinical trials | sacituzumab govitecan |
Search PubMed titles | sacituzumab govitecan |
Search PubMed titles/abstracts | sacituzumab govitecan |